Who are Influenza vaccine GSK2340274A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Seasonal trivalent vaccine, trivalent seasonal influenza vaccine, HD-TIV, Influsplit SSW® 2005/2006, Pandemic influenza A/H1N1 vaccine, Flublok™ Quadrivalent by Sanofi, Inc..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/influenza-vaccine-gsk2340274a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Influenza vaccine GSK2340274A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influenza vaccine GSK2340274A (Influenza vaccine GSK2340274A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology.

phase 3 Influenza vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Influenza vaccine GSK2340274A (Influenza vaccine GSK2340274A) — GlaxoSmithKline. GSK2340274A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Influenza vaccine GSK2340274A TARGET	Influenza vaccine GSK2340274A	GlaxoSmithKline	phase 3	Influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
HD-TIV	HD-TIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine
Influsplit SSW® 2005/2006	Influsplit SSW® 2005/2006	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

GlaxoSmithKline · 8 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Seqirus · 2 drugs in this class
MedImmune LLC · 1 drug in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Protein Sciences Corporation · 1 drug in this class
ModernaTX, Inc. · 1 drug in this class
Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Influenza vaccine GSK2340274A — Competitive Intelligence Brief. https://druglandscape.com/ci/influenza-vaccine-gsk2340274a. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab